- ASSISTANT PROFESSOR Medicine, Endocrinology, Diabetes and Bone Disease
Shelly Im, a graduate of New York University’s School of Medicine, completed her internship and residency in Internal Medicine at Mount Sinai Hospital and stayed on for an additional year as a hospitalist in the Division of General Medicine. She returned to New York University to pursue her fellowship training in Endocrinology, Diabetes and Metabolism. During her training she participated in research projects involving thyroid disease in pregnancy as well as atypical fractures related to bisphosphonate use.
Dr. Im is currently the Medical Director for the Diabetes & Cardiovascular Alliance Program at Mount Sinai Hospital, collaborating with certified diabetes educators to optimize Diabetes management in the local community. She sees patients at Mount Sinai Hospital affiliated off-sites in Bay Ridge, Brooklyn, Jackson Heights, Queens, and Washington Heights in Manhattan. Her clinical interests include Diabetes Mellitus, thyroid disease, thyroid cancer, and osteoporosis.
Markman LH, Allison MB, Rosenberg ZS, Vieira RL, Babb JS, Tejwani NC, Im SA, Peck V. A Retrospective Review of Patients with Atypical Femoral Fractures While on Long-Term Bisphosphonates: Including Pertinent Biochemical and Imaging Studies. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2013 Jan;.
La Rocca Vieira R, Rosenberg ZS, Allison MB, Im SA, Babb J, Peck V. Frequency of incomplete atypical femoral fractures in asymptomatic patients on long-term bisphosphonate therapy. AJR. American journal of roentgenology 2012 May; 198(5).
Reh A, Chaudhry S, Mendelsohn F, Im SA, Rolnitzky L, Amarosa A, Levitz M, Srinivasa S, Krey L, Berkeley AS, Grifo JA, Danoff A. Effect of autoimmune thyroid disease in older euthyroid infertile woman during the first 35 days of an IVF cycle. Fertility and sterility 2011 Mar; 95(3).
Honiden S, Schultz A, Im SA, Nierman DM, Gong MN. Early versus late intravenous insulin administration in critically ill patients. Intensive Care Medicine 2008; 34: 881-887.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Im did not report having any of the following types of financial relationships with industry during 2013 and/or 2014: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Atran Berg Laboratory Building Floor 4th floor
1428 Madison Avenue
New York, NY 10029